
Adamis Pharmaceuticals Corporation ADMP
Quartalsbericht 2023-Q3
hinzugefügt 14.11.2023
Adamis Pharmaceuticals Corporation Kurzfristige Verbindlichkeiten 2011-2026 | ADMP
Kurzfristige Verbindlichkeiten Jährlich Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 M | 11.2 M | 19.9 M | 10.2 M | 11.6 M | 8.79 M | 8.61 M | 2.75 M | 3.39 M | 4.68 M | 2.89 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 19.9 M | 2.75 M | 8.67 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
China Pharma Holdings
CPHI
|
5.02 M | $ 0.63 | - | $ 11 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 22.7 | 0.22 % | $ 1.05 B | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 8.06 | 0.12 % | $ 413 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.17 | 3.93 % | $ 44.6 M | ||
|
Rockwell Medical
RMTI
|
16.6 M | $ 1.05 | 2.45 % | $ 24.5 M | ||
|
Solid Biosciences
SLDB
|
33.5 M | $ 6.9 | -3.36 % | $ 604 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.33 | -8.46 % | $ 2.89 M | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 4.97 | -2.45 % | $ 1.81 B | ||
|
Harrow Health
HROW
|
96.3 M | $ 35.2 | 3.53 % | $ 1.29 B | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
Tilray
TLRY
|
433 M | $ 6.44 | -0.23 % | $ 3.98 B | ||
|
Evolus
EOLS
|
75.3 M | $ 4.61 | -1.6 % | $ 297 M | ||
|
Veru
VERU
|
11.9 M | $ 2.32 | 0.85 % | $ 313 M | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Viatris
VTRS
|
6.75 B | $ 13.47 | 1.35 % | $ 16.2 B | ||
|
Relmada Therapeutics
RLMD
|
6.43 M | $ 6.08 | 3.73 % | $ 240 M | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | ||
|
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
SCYNEXIS
SCYX
|
5.73 M | $ 0.87 | -0.3 % | $ 43.4 M | ||
|
TherapeuticsMD
TXMD
|
6.85 M | $ 2.29 | -1.07 % | $ 23.9 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 0.78 | 2.14 % | $ 3.36 M | ||
|
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.42 | -2.02 % | $ 319 M | ||
|
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | ||
|
Perrigo Company plc
PRGO
|
1.01 B | $ 9.76 | 1.99 % | $ 1.35 B | ||
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 0.95 | -1.82 % | $ 102 M | ||
|
Assertio Holdings
ASRT
|
128 M | $ 16.17 | 15.46 % | $ 104 M | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M |